Role of Adjuvant Treatment in Esophageal Cancer With Incidental Pathologic Node Positivity

被引:10
作者
Gao, Sarah J.
Park, Henry S.
Corso, Christopher D.
Rutter, Charles E.
Kim, Anthony W.
Johung, Kimberly L.
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06511 USA
[2] Hartford Hosp, Dept Radiat Oncol, Hartford, CT 06115 USA
[3] Univ Southern Calif, Keck Sch Med, Dept Thorac Surg, Los Angeles, CA 90033 USA
关键词
PHASE-III TRIAL; SQUAMOUS-CELL CARCINOMA; GASTROESOPHAGEAL JUNCTION; POSTOPERATIVE CHEMORADIATION; NEOADJUVANT THERAPY; RADIATION-THERAPY; GASTRIC-CANCER; MARGIN STATUS; SURGERY; CHEMORADIOTHERAPY;
D O I
10.1016/j.athoracsur.2017.01.092
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The optimal adjuvant treatment for cT1-2 N0 esophageal cancer patients found to have pathologic nodal involvement after an upfront operation is unclear. This study investigated the effects of postoperative chemotherapy and chemoradiation therapy on overall survival in cT1-2 N0 patients with incidental pN(+) disease stratified by margin status. Methods. We identified cT1-2 N0 M0 esophageal carcinoma patients from 2004 to 2012 from the National Cancer Data Base. Patients were categorized as having received surgical resection alone, surgical resection followed by chemotherapy (SDCT), and surgical resection followed by concurrent chemoradiation therapy (SDCRT). Subset analyses were conducted on margin-negative and margin-positive patients. Overall survival was compared by Kaplan-Meier estimation, the log-rank test, and multivariable Cox regression analysis. Results. Among 443 patients, 52.6% received surgical resection alone, 18.7% received SDCT, and 28.6% received SDCRT. Significantly more adenocarcinoma patients received adjuvant treatment (50.8%) than squamous cell carcinoma patients (27.7%, p = 0.001). On multivariable analysis, SDCT (hazard ratio, 0.64; 95% confidence interval, 0.45 to 0.91; p = 0.014) and SDCRT (hazard ratio, 0.73; 95% confidence interval,. 0.55 to 0.98; p = 0.038) both were associated with significantly increased overall survival. These findings persisted among margin-negative patients. However, in margin-positive patients, SDCRT (hazard ratio, 0.29; p = 0.002) was the only treatment arm that was associated with significantly improved survival compared with surgical resection alone. Conclusions. Among cT1-2 N0 pN(+) esophageal cancer patients, adjuvant chemotherapy may be sufficient for margin-negative patients, whereas adjuvant chemoradiation therapy appears necessary for margin-positive patients. Further prospective studies are needed to confirm the results. (C) 2017 by The Society of Thoracic Surgeons
引用
收藏
页码:267 / 274
页数:8
相关论文
共 31 条
  • [1] Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction
    Adelstein, David J.
    Rice, Thomas W.
    Rybicki, Lisa A.
    Saxton, Jerrold P.
    Videtic, Gregory M. M.
    Murthy, Sudish C.
    Mason, David P.
    Rodriguez, Cristina P.
    Ives, Denise I.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (10) : 1264 - 1269
  • [2] Esophageal and Esophagogastric Junction Cancers, Version 1.2015
    Ajani, Jaffer A.
    D'Amico, Thomas A.
    Almhanna, Khaldoun
    Bentrem, David J.
    Besh, Stephen
    Chao, Joseph
    Das, Prajnan
    Denlinger, Crystal
    Fanta, Paul
    Fuchs, Charles S.
    Gerdes, Hans
    Glasgow, Robert E.
    Hayman, James A.
    Hochwald, Steven
    Hofstetter, Wayne L.
    Ilson, David H.
    Jaroszewski, Dawn
    Jasperson, Kory
    Keswani, Rajesh N.
    Kleinberg, Lawrence R.
    Korn, W. Michael
    Leong, Stephen
    Lockhart, A. Craig
    Mulcahy, Mary F.
    Orringer, Mark B.
    Posey, James A.
    Poultsides, George A.
    Sasson, Aaron R.
    Scott, Walter J.
    Strong, Vivian E.
    Varghese, Thomas K., Jr.
    Washington, Mary Kay
    Willett, Christopher G.
    Wright, Cameron D.
    Zelman, Debra
    McMillian, Nicole
    Sundar, Hema
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (02): : 194 - 227
  • [3] LOCAL FAILURE AND MARGIN STATUS IN EARLY-STAGE BREAST-CARCINOMA TREATED WITH CONSERVATION SURGERY AND RADIATION-THERAPY
    ANSCHER, MS
    JONES, P
    PROSNITZ, LR
    BLACKSTOCK, W
    HEBERT, M
    REDDICK, R
    TUCKER, A
    DODGE, R
    LEIGHT, G
    IGLEHART, JD
    ROSENMAN, J
    [J]. ANNALS OF SURGERY, 1993, 218 (01) : 22 - 28
  • [4] Bédard ELR, 2001, CANCER-AM CANCER SOC, V91, P2423, DOI 10.1002/1097-0142(20010615)91:12<2423::AID-CNCR1277>3.3.CO
  • [5] 2-T
  • [6] The National Cancer Data Base: A powerful initiative to improve cancer care in the United States
    Bilimoria, Karl Y.
    Stewart, Andrew K.
    Winchester, David P.
    Ko, Clifford Y.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (03) : 683 - 690
  • [7] ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES
    DEYO, RA
    CHERKIN, DC
    CIOL, MA
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) : 613 - 619
  • [8] Post-surgical chemotherapy versus surgery alone for resectable gastric cancer
    Diaz-Nieto, Rafael
    Orti-Rodriguez, Rafael
    Winslet, Marc
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (09):
  • [9] Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma
    Franko, Jan
    Voynov, George
    Goldman, Charles D.
    [J]. ANNALS OF THORACIC SURGERY, 2016, 101 (03) : 1123 - 1130
  • [10] Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation
    Gabriel, Emmanuel
    Attwood, Kristopher
    Du, William
    Tuttle, Rebecca
    Alnaji, Raed M.
    Nurkin, Steven
    Malhotra, Usha
    Hochwald, Steven N.
    Kukar, Moshim
    [J]. JAMA SURGERY, 2016, 151 (03) : 234 - 245